PriceTargets.com logo

Privia Health Group - PRVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.80
  • Forecasted Upside: 28.83%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 12 Buy Ratings
  • 2 Strong Buy Ratings
$19.25 As of 12/30/2024 12:45 PM ET
▼ -0.6 (-3.02%)

This chart shows the closing price for PRVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Privia Health Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRVA

Analyst Price Target is $24.80
▲ +28.83% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $24.80, with a high forecast of $29.00 and a low forecast of $20.00. The average price target represents a 28.83% upside from the last price of $19.25.

This chart shows the closing price for PRVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 16 investment analysts is to buy stock in Privia Health Group. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 2 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 2 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024MacquarieInitiated CoverageOutperform$25.00
11/29/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$27.00 ➝ $28.00
11/8/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$19.00 ➝ $21.00
11/8/2024Truist FinancialBoost TargetBuy ➝ Buy$24.00 ➝ $27.00
10/11/2024KeyCorpInitiated CoverageOverweight$23.00
10/10/2024KeyCorpUpgradeStrong-Buy
8/26/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$23.00 ➝ $24.00
8/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$28.00 ➝ $28.00
7/9/2024Evercore ISILower TargetOutperform ➝ Outperform$23.00 ➝ $20.00
5/30/2024Baird R WUpgradeStrong-Buy
5/30/2024Robert W. BairdInitiated CoverageOutperform$23.00
5/20/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$22.00 ➝ $19.00
5/15/2024Truist FinancialLower TargetBuy ➝ Buy$28.00 ➝ $24.00
5/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$37.00 ➝ $26.00
5/1/2024Stifel NicolausLower TargetBuy ➝ Buy$28.00 ➝ $24.00
4/22/2024CitigroupInitiated CoverageBuy$25.00
3/19/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$41.00 ➝ $37.00
3/6/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$38.00 ➝ $30.00
3/6/2024BarclaysInitiated CoverageEqual Weight$22.00
3/1/2024UBS GroupLower TargetBuy ➝ Buy$31.00 ➝ $29.00
3/1/2024TD CowenLower TargetOutperform ➝ Outperform$30.00 ➝ $26.00
2/29/2024Truist FinancialLower TargetBuy ➝ Buy$32.00 ➝ $28.00
2/28/2024Evercore ISILower TargetOutperform ➝ Outperform$26.00 ➝ $25.00
2/26/2024Jefferies Financial GroupInitiated CoverageBuy$33.00 ➝ $25.00
2/22/2024Bank of AmericaDowngradeBuy ➝ Neutral$27.00 ➝ $21.00
12/6/2023JMP SecuritiesInitiated CoverageOutperform$27.00
11/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$43.00 ➝ $38.00
10/11/2023Evercore ISILower Target$32.00 ➝ $26.00
8/18/2023UBS GroupLower TargetBuy ➝ Buy$35.00 ➝ $32.00
8/15/2023TD CowenLower TargetOutperform ➝ Outperform$44.00 ➝ $35.00
6/12/2023Evercore ISIInitiated CoverageOutperform$34.00
5/5/2023SVB SecuritiesBoost Target$39.00 ➝ $40.00
4/11/2023StephensInitiated CoverageOverweight$33.00
3/9/2023Royal Bank of CanadaInitiated CoverageOutperform$36.00
3/7/2023Credit Suisse GroupReiterated RatingOutperform$41.00
2/3/2023The Goldman Sachs GroupInitiated CoverageBuy$32.00
1/9/2023BTIG ResearchLower Target$45.00 ➝ $40.00
12/8/2022Stifel NicolausInitiated CoverageBuy$28.00
12/8/2022UBS GroupInitiated CoverageBuy$30.00
11/17/2022Truist FinancialLower Target$41.00
11/17/2022Piper SandlerLower Target$42.00
11/11/2022Canaccord Genuity GroupLower TargetBuy$50.00 ➝ $43.00
11/11/2022Leerink PartnersLower TargetOutperform$46.00 ➝ $39.00
9/7/2022Truist FinancialBoost TargetBuy$48.00 ➝ $54.00
8/25/2022Canaccord Genuity GroupBoost Target$45.00 ➝ $50.00
8/15/2022BTIG ResearchBoost Target$45.00
8/12/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
8/12/2022Truist FinancialBoost TargetBuy$40.00 ➝ $48.00
8/12/2022GuggenheimBoost TargetBuy$36.00 ➝ $51.00
8/12/2022Credit Suisse GroupBoost TargetOutperform$33.00 ➝ $41.00
8/12/2022Leerink PartnersBoost TargetOutperform$33.00 ➝ $46.00
8/12/2022CowenBoost TargetOutperform$35.00 ➝ $44.00
8/12/2022CowenBoost TargetOutperform$35.00 ➝ $44.00
7/14/2022Truist FinancialBoost TargetBuy$36.00 ➝ $40.00
6/29/2022Canaccord Genuity GroupBoost Target$29.00 ➝ $40.00
5/13/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$44.00 ➝ $29.00
5/3/2022Bank of AmericaInitiated CoverageBuy$27.00
4/28/2022BTIG ResearchInitiated CoverageBuy$35.00
3/29/2022GuggenheimInitiated CoverageBuy$35.00
3/25/2022Leerink PartnersBoost TargetOutperform$43.00 ➝ $44.00
3/24/2022Canaccord Genuity GroupLower TargetBuy$50.00 ➝ $44.00
2/22/2022CowenUpgradeMarket Perform ➝ Outperform$35.00
1/3/2022Jefferies Financial GroupInitiated CoverageBuy$33.00
12/8/2021Leerink PartnersBoost TargetOutperform$42.00 ➝ $43.00
11/9/2021Leerink PartnersBoost TargetOutperform$35.00 ➝ $42.00
10/13/2021Truist FinancialLower TargetBuy$40.00 ➝ $32.00
9/27/2021Leerink PartnersInitiated CoverageOutperform$35.00
9/9/2021CowenInitiated CoverageMarket Perform$31.00
7/14/2021Piper SandlerBoost TargetOverweight$40.00 ➝ $48.00
6/30/2021Credit Suisse GroupBoost TargetOutperform$44.00 ➝ $57.00
5/24/2021Truist FinancialInitiated CoverageBuy$40.00
5/24/2021Piper SandlerInitiated CoverageOverweight$40.00
5/24/2021JPMorgan Chase & Co.Initiated CoverageOverweight$40.00
5/24/2021William BlairInitiated CoverageOutperform
5/24/2021Credit Suisse GroupInitiated CoverageOutperform$44.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Privia Health Group logo
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Read More

Today's Range

Now: $19.25
Low: $19.16
High: $20.12

50 Day Range

MA: $20.50
Low: $17.48
High: $22.80

52 Week Range

Now: $19.25
Low: $15.92
High: $24.05

Volume

96,546 shs

Average Volume

831,402 shs

Market Capitalization

$2.31 billion

P/E Ratio

192.52

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Privia Health Group?

The following sell-side analysts have issued research reports on Privia Health Group in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Macquarie, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for PRVA.

What is the current price target for Privia Health Group?

0 Wall Street analysts have set twelve-month price targets for Privia Health Group in the last year. Their average twelve-month price target is $24.80, suggesting a possible upside of 28.8%. UBS Group AG has the highest price target set, predicting PRVA will reach $29.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $20.00 for Privia Health Group in the next year.
View the latest price targets for PRVA.

What is the current consensus analyst rating for Privia Health Group?

Privia Health Group currently has 2 hold ratings, 12 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRVA will outperform the market and that investors should add to their positions of Privia Health Group.
View the latest ratings for PRVA.

What other companies compete with Privia Health Group?

Other companies that are similar to Privia Health Group include Hims & Hers Health, Option Care Health, Guardant Health, Sotera Health and Veracyte. Learn More about companies similar to Privia Health Group.

How do I contact Privia Health Group's investor relations team?

The company's listed phone number is 571-366-8850 and its investor relations email address is [email protected]. The official website for Privia Health Group is www.priviahealth.com. Learn More about contacing Privia Health Group investor relations.